+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CD19-targeted CAR-T Cell Therapy Market - Global Forecast 2026-2032- Product Image
CD19-targeted CAR-T Cell Therapy Market - Global Forecast 2026-2032- Product Image
Sale

CD19-targeted CAR-T Cell Therapy Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6139750
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The CD19-targeted CAR-T Cell Therapy Market is projected to reach USD 7.29 Billion in 2026. It is expected to continue growing at a CAGR of 18.15%, reaching USD 19.88 Billion by 2032.

CD19-Targeted CAR-T Therapy: Executive Overview

CD19-targeted chimeric antigen receptor T-cell therapy is an advanced cellular immunotherapy in which a patient’s T cells are genetically modified to recognize CD19, a protein expressed on many B-cell malignancies. Its clinical use is established in selected relapsed or refractory B-cell cancers, while ongoing research is examining earlier treatment lines, additional hematologic diseases, durability, outpatient delivery, and applications beyond oncology.

Clinical Practice Is Shifting Toward Earlier, Safer, and More Accessible Use

The field is moving from highly specialized rescue treatment toward broader integration across treatment pathways. Important shifts include earlier referral for eligible patients, improved lymphodepletion and bridging strategies, stronger management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and greater attention to long-term monitoring. Manufacturing automation, decentralized collection and logistics, standardized care pathways, and health-system investment are also shaping access and operational readiness.

Artificial Intelligence Is Strengthening Selection, Manufacturing, and Monitoring

Artificial intelligence can support CD19-targeted CAR-T development by analyzing clinical, genomic, imaging, and manufacturing data. Potential applications include identifying patients most likely to respond, detecting relapse or treatment complications earlier, optimizing construct and process parameters, and improving quality control. Translation into routine care requires representative datasets, prospective validation, explainable models, cybersecurity safeguards, and clear accountability because treatment decisions involve complex biology and high clinical risk.

Regional Insights: Infrastructure and Access Determine Adoption

North America has extensive experience with cellular-therapy centers, specialized diagnostics, and regulatory pathways, although cost, capacity, and geographic access remain important considerations. Europe is supported by sophisticated oncology networks and coordinated regulatory activity, with variation in reimbursement and national implementation. Asia-Pacific combines advanced capabilities in markets such as Japan, South Korea, China, and Australia with substantial differences in infrastructure and affordability. Latin America is developing referral, manufacturing, and regulatory capacity but faces uneven access. The Middle East is investing in tertiary-care and precision-medicine infrastructure, while Africa’s progress is concentrated in leading centers and constrained by specialist capacity, logistics, and financing.

Group Insights: Collaboration Shapes Clinical and Manufacturing Capacity

ASEAN countries are building capability unevenly, making regional referral networks, workforce development, and harmonized standards particularly valuable. BRICS members span major research, manufacturing, and clinical systems but differ considerably in regulatory maturity, reimbursement, and access. The European Union benefits from cross-border scientific and regulatory coordination, while national health-system decisions continue to influence implementation. G7 members contribute substantial clinical research, infrastructure, and policy experience. GCC countries are expanding advanced-care capacity through centralized institutions and international partnerships. NATO members represent a broad set of health systems whose cooperation can support resilience in specialized supply chains, although civilian clinical priorities remain distinct from alliance objectives.

Country Insights: National Capacity Varies Across the Treatment Pathway

The United States and Canada have established referral and cellular-therapy networks, with access shaped by payer policy, center capacity, and geography. Germany, France, Italy, Spain, and the United Kingdom have advanced hematology services, while reimbursement, commissioning, and cross-border referral arrangements differ. Australia and Japan maintain sophisticated oncology infrastructure with geographically dispersed populations requiring strong logistics. China and South Korea are expanding clinical, manufacturing, and regulatory capabilities within evolving frameworks. India is developing specialized centers and domestic expertise while affordability and distribution remain important. Brazil and Mexico are strengthening advanced oncology services but face regional disparities. Russia’s capacity is shaped by domestic research, regulation, and access to specialized infrastructure.

Action Priorities for Industry Leaders: Build Reliable, Evidence-Led Care Pathways

Leaders should prioritize durable clinical evidence, transparent patient-selection criteria, and post-treatment surveillance that captures both benefit and late risk. Operationally, they should strengthen referral coordination, collection and transport reliability, manufacturing quality systems, center accreditation, and workforce training. Partnerships with hospitals, regulators, payers, and patient organizations can improve equitable access and preparedness. Artificial-intelligence programs should begin with clinically defined use cases, independent validation, human oversight, and robust data governance rather than technology deployment alone.

Research Methodology: Evidence-Based Synthesis of the CD19 CAR-T Landscape

This executive summary synthesizes established clinical knowledge and structural trends relevant to CD19-targeted CAR-T therapy, including treatment biology, care delivery, manufacturing, safety management, regulation, infrastructure, and access. Regional, group, and country discussions are qualitative and focus on documented differences in healthcare capacity, policy, research activity, and implementation conditions. No market estimates, market shares, forecasts, or company-level comparisons are used. Findings should be interpreted alongside current clinical guidelines, regulatory decisions, peer-reviewed studies, and local reimbursement policies.

Conclusion: Sustainable Progress Depends on Clinical Value and System Readiness

CD19-targeted CAR-T therapy has reshaped treatment options for selected B-cell malignancies, but its broader impact depends on more than therapeutic efficacy. Consistent outcomes require timely referral, specialized infrastructure, disciplined safety management, reliable manufacturing, long-term follow-up, and equitable financing. Regions and countries that align evidence generation with workforce, regulatory, and care-delivery investment will be better positioned to extend the benefits of this therapy responsibly.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. CD19-targeted CAR-T Cell Therapy Market, by Product Type
7.1. Introduction
7.2. Allogeneic
7.2.1. Hla Matched
7.2.2. Universal Donor
7.3. Autologous
7.3.1. Cryopreserved
7.3.2. Fresh
8. CD19-targeted CAR-T Cell Therapy Market, by Indication
8.1. Introduction
8.2. Acute Lymphoblastic Leukemia
8.3. Chronic Lymphocytic Leukemia
8.4. Diffuse Large B-Cell Lymphoma
8.4.1. Refractory
8.4.2. Relapsed
8.5. Follicular Lymphoma
8.6. Mantle Cell Lymphoma
9. CD19-targeted CAR-T Cell Therapy Market, by Line Of Therapy
9.1. Introduction
9.2. First-Line
9.3. Second-Line
9.4. Third-Line & Beyond
10. CD19-targeted CAR-T Cell Therapy Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals & Specialty Centers
10.4. Research Institutes
11. CD19-targeted CAR-T Cell Therapy Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. CD19-targeted CAR-T Cell Therapy Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. CD19-targeted CAR-T Cell Therapy Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Allogene Therapeutics
15.2. Autolus Therapeutics plc
15.3. Bristol Myers Squibb Company
15.4. Cabaletta Bio
15.5. Caribou Biosciences Inc.
15.6. Carsgen Therapeutics
15.7. Cellectis
15.8. Fosun Kite Biotechnology Co. Ltd.
15.9. Immuneel Therapeutics Pvt. Ltd.
15.10. ImmunoACT Pvt. Ltd.
15.11. JW Therapeutics
15.12. Kite Pharma Inc.
15.13. Legend Biotech Corporation
15.14. Lyell Immunopharma
15.15. Mustang Bio Inc.
15.16. Novartis AG
15.17. Precision BioSciences Inc.
15.18. Servier Laboratories
15.19. Wugen
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global CD19-targeted CAR-T Cell Therapy Market, Years Considered for the Study
FIGURE 2. Global CD19-targeted CAR-T Cell Therapy Market, Research Design
FIGURE 3. Global CD19-targeted CAR-T Cell Therapy Market, Research Framework
FIGURE 4. Global CD19-targeted CAR-T Cell Therapy Market, Data Triangulation
FIGURE 5. Global CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 11. Global CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global CD19-targeted CAR-T Cell Therapy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global CD19-targeted CAR-T Cell Therapy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global CD19-targeted CAR-T Cell Therapy Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global CD19-targeted CAR-T Cell Therapy Market Segmentation & Coverage
TABLE 2. Global CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 3. Global CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Hla Matched Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Hla Matched Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Hla Matched Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Universal Donor Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Universal Donor Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Universal Donor Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Cryopreserved Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Cryopreserved Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Cryopreserved Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Fresh Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Fresh Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Fresh Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 23. Global Acute Lymphoblastic Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Acute Lymphoblastic Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Acute Lymphoblastic Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Chronic Lymphocytic Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Chronic Lymphocytic Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Chronic Lymphocytic Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Diffuse Large B-Cell Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Diffuse Large B-Cell Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Diffuse Large B-Cell Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Refractory Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Refractory Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Refractory Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Relapsed Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Relapsed Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Relapsed Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Follicular Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Follicular Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Follicular Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Mantle Cell Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Mantle Cell Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Mantle Cell Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 45. Global First-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global First-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global First-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Second-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Second-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Second-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Third-Line & Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Third-Line & Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Third-Line & Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Hospitals & Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Hospitals & Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Hospitals & Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. North America CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. North America CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 75. North America CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 76. North America CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 77. North America CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. North America CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 79. North America CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 80. North America CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 83. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 84. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 85. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 86. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 87. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 88. Latin America CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 92. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 93. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 94. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 95. Europe CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 96. Europe CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 99. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 100. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 101. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 102. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 103. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 104. Middle East CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 108. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 109. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 111. Africa CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 112. Africa CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. Global CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 116. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 117. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 118. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 119. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 120. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 121. ASEAN CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 124. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 125. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 126. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 127. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 128. GCC CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 129. GCC CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 133. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 134. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 135. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 136. European Union CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 137. European Union CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 140. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 141. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 142. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 143. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 144. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 145. BRICS CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 148. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 149. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 150. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 152. G7 CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 153. G7 CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 157. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 158. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 160. NATO CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 161. NATO CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. Global CD19-targeted CAR-T Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. United States CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 164. United States CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 165. United States CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 166. United States CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 167. United States CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 168. United States CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 169. United States CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 170. United States CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Canada CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 172. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 174. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 175. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 176. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 177. Canada CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 178. Canada CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Mexico CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 180. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 181. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 182. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 183. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 185. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 186. Mexico CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Brazil CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 188. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 189. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 190. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 191. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 192. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 193. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 194. Brazil CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 196. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 197. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 198. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 199. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 200. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 201. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 202. United Kingdom CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Germany CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 204. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 205. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 206. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 207. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 209. Germany CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 210. Germany CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. France CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 212. France CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 213. France CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 214. France CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 215. France CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 216. France CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 217. France CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 218. France CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Russia CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 220. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 221. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 222. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 223. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 224. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 225. Russia CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 226. Russia CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Italy CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 228. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 230. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 231. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 232. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 233. Italy CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 234. Italy CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Spain CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 236. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 237. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 238. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 239. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 240. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 241. Spain CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 242. Spain CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. China CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 244. China CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 245. China CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 246. China CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 247. China CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 248. China CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 249. China CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 250. China CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. India CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 252. India CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 253. India CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 254. India CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 255. India CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 256. India CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 257. India CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 258. India CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. Japan CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 260. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 261. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 262. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 263. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 264. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 265. Japan CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 266. Japan CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. Australia CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 268. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 269. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 270. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 271. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 272. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 273. Australia CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 274. Australia CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. South Korea CD19-targeted CAR-T Cell Therapy Market Size, 2017-2032 (USD Million)
TABLE 276. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 277. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Allogeneic, 2017-2032 (USD Million)
TABLE 278. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Autologous, 2017-2032 (USD Million)
TABLE 279. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Indication, 2017-2032 (USD Million)
TABLE 280. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Diffuse Large B-Cell Lymphoma, 2017-2032 (USD Million)
TABLE 281. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 282. South Korea CD19-targeted CAR-T Cell Therapy Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Global CD19-targeted CAR-T Cell Therapy Market Share, by Key Player, 2025
TABLE 284. Global CD19-targeted CAR-T Cell Therapy Market, Key Experts

Companies Mentioned

  • Allogene Therapeutics
  • Autolus Therapeutics plc
  • Bristol Myers Squibb Company
  • Cabaletta Bio
  • Caribou Biosciences Inc.
  • Carsgen Therapeutics
  • Cellectis
  • Fosun Kite Biotechnology Co. Ltd.
  • Immuneel Therapeutics Pvt. Ltd.
  • ImmunoACT Pvt. Ltd.
  • JW Therapeutics
  • Kite Pharma Inc.
  • Legend Biotech Corporation
  • Lyell Immunopharma
  • Mustang Bio Inc.
  • Novartis AG
  • Precision BioSciences Inc.
  • Servier Laboratories
  • Wugen

Related Topics

Related Reports

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 198 Pages
  • Global
From
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - Product Image

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

  • Report
  • 598 Pages
  • Global
From
CAR T - Cell Therapy - Competitive Landscape, 2026 - Product Image

CAR T - Cell Therapy - Competitive Landscape, 2026

  • Report
  • 500 Pages
  • Global
From
CAR T-Cell Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

CAR T-Cell Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 111 Pages
  • Global
From
CAR T-cell Therapy Market - Global Forecast 2026-2032 - Product Image

CAR T-cell Therapy Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.